Novartis updates on Phase III PARAGON-HF trial in heart failure

• PARAGON study narrowly misses statistical significance on the primary endpoint; overall safety profile confirmed
• Totality of evidence suggests potential clinically important benefit; results will be presented in September at the ESC Congress 2019, the annual meeting of the European Society of Cardiology (ESC) 
• Novartis plans to engage in conversations with clinical experts and regulators on next steps

https://www.marketscreener.com/NOVARTIS-9364983/news/Novartis-provides-update-on-Phase-III-PARAGON-HF-trial-in-heart-failure-patients-with-preserved-ej-28973563/